Posted by Michael Wonder on 06 Jul 2021
FDA grants priority review for Levo Therapeutics’ new drug application for LV-101 (intranasal carbetocin) for the treatment of Prader-Willi syndrome
6 July 2021 - Levo Therapeutics announced today that the U.S. FDA has granted priority review for its new drug application for LV-101 (intranasal carbetocin) as a treatment for hyperphagia and behavioural distress associated with Prader-Willi syndrome.
ccordingly, Levo expects FDA’s decision on the approval of LV-101 by the end of this year.
